Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis

Infection and Immunity

Volumn 82, Issue 4, 2014, Pages 1710-1718

  Liechti, Fabian D ^a   Grandgirard, Denis ^a   Leppert, David ^b   Leib, Stephen L ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c SPIEZ LABORATORY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CHEMOKINE; CIPEMASTAT; COLLAGEN; COLLAGENASE 3; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; RO 327315; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; APOPTOSIS; ARTICLE; BODY WEIGHT; BRAIN CORTEX; BRAIN INJURY; BRAIN NECROSIS; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; INFANT; MORPHOMETRICS; MORTALITY; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; RAT; STREPTOCOCCUS PNEUMONIAE; WEIGHT REDUCTION;

ADAM PROTEINS; ANIMALS; APOPTOSIS; BRAIN INJURIES; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; HYDROXAMIC ACIDS; IMIDAZOLES; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MENINGITIS, PNEUMOCOCCAL; PEROXIDASE; RATS; SULFONAMIDES; WEIGHT LOSS;

EID: 84896447812     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00073-14     Document Type: Article

References (58)

1. Koedel U, Scheld WM, Pfister HW. 2002. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect. Dis. 2:721-736. http://dx.doi.org/10.1016/S1473-3099(02)00450-4.
2. Brouwer MC, Heckenberg SG, de Gans J, Spanjaard L, Reitsma JB, van de Beek D. 2010. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. Neurology 75:1533-1539. http://dx.doi.org/10.1212/WNL.0b013e3181f96297.
3. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. 2010. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect. Dis. 10:317-328. http://dx.doi.org/10.1016/S1473-3099(10)70048-7.
4. Chandran A, Herbert H, Misurski D, Santosham M. 2011. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr. Infect. Dis. J. 30:3-6. http://dx.doi.org/10.1097/INF.0b013e3181ef25f7.
5. Grandgirard D, Steiner O, Tauber MG, Leib SL. 2007. An infant mouse model of brain damage in pneumococcal meningitis. Acta Neuropathol. 114:609-617. http://dx.doi.org/10.1007/s00401-007-0304-8.
6. Bifrare YD, Gianinazzi C, Imboden H, Leib SL, Tauber MG. 2003. Bacterial meningitis causes two distinct forms of cellular damage in the hippocampal dentate gyrus in infant rats. Hippocampus 13:481-488. http://dx.doi.org/10.1002/hipo.10142.
7. Nau R, Soto A, Bruck W. 1999. Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J. Neuropathol Exp. Neurol. 58:265-274. http://dx.doi.org/10.1097/00005072-199903000-00006.
8. van Furth AM, Roord JJ, van Furth R. 1996. Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect. Immun. 64:4883-4890.
9. Grandgirard D, Burri M, Agyeman P, Leib SL. 2012. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob. Agents Chemother. 56:4289-4295. http://dx.doi.org/10.1128/AAC.00674-12.
10. Maskos K, Fernandez-Catalan C, Huber R, Bourenkov GP, Bartunik H, Ellestad GA, Reddy P, Wolfson MF, Rauch CT, Castner BJ, Davis R, Clarke HR, Petersen M, Fitzner JN, Cerretti DP, March CJ, Paxton RJ, Black RA, Bode W. 1998. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc. Natl. Acad. Sci. U. S. A. 95:3408-3412. http://dx.doi.org/10.1073/pnas.95.7.3408.
11. Rosenberg GA. 2002. Matrix metalloproteinases in neuroinflammation. Glia 39:279-291. http://dx.doi.org/10.1002/glia.10108.
12. Grandgirard D, Leib SL. 2006. Strategies to prevent neuronal damage in paediatric bacterial meningitis. Curr. Opin. Pediatr. 18:112-118. http://dx.doi.org/10.1097/01.mop.0000193292.09894.b7.
13. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW. 1998. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 44:592-600. http://dx.doi.org/10.1002/ana.410440404.
14. Leib SL, Leppert D, Clements J, Täuber MG. 2000. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect. Immun. 68:615-620. http://dx.doi.org/10.1128/IAI.68.2.615-620.2000.
15. Leppert D, Lindberg RL, Kappos L, Leib SL. 2001. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 36:249-257. http://dx.doi.org/10.1016/S0165-0173(01)00101-1.
16. Kastenbauer S, Pfister HW. 2003. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 126:1015-1025. http://dx.doi.org/10.1093/brain/awg113.
17. Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knauper V, Docherty AJ, Murphy G. 2000. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473:275-279. http://dx.doi.org/10.1016/S0014-5793(00)01528-3.
18. Sellner J, Leib SL. 2006. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis. 21:647-656. http://dx.doi.org/10.1016/j.nbd.2005.09.007.
19. Leppert D, Leib SL, Grygar C, Miller KM, Schaad UB, Hollander GA. 2000. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin. Infect. Dis. 31:80-84. http://dx.doi.org/10.1086/313922.
20. Yushchenko M, Weber F, Mader M, Scholl U, Maliszewska M, Tumani H, Felgenhauer K, Beuche W. 2000. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110:244-251. http://dx.doi.org/10.1016/S0165-5728(00)00339-8.
21. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK, BioMS Study Group. 2009. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 35:117-127. http://dx.doi.org/10.1016/j.nbd.2009.04.010.
22. Brinckerhoff CE, Matrisian LM. 2002. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3:207-214. http://dx.doi.org/10.1038/nrm763.
23. Catterall JB, Cawston TE. 2003. Assays of matrix metalloproteinases (MMPs) and MMP inhibitors: bioassays and immunoassays applicable to cell culture medium, serum, and synovial fluid. Methods Mol. Biol. 225: 353-364. http://dx.doi.org/10.1385/1-59259-374-7:353.
24. Dormán G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K, Kovacs L, Ferdinandy P. 2010. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 70: 949-964. http://dx.doi.org/10.2165/11318390-000000000-00000.
25. Jackson C, Nguyen M, Arkell J, Sambrook P. 2001. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis-targetting gelatinase A activation. Inflamm. Res. 50:183-186. http://dx.doi.org/10.1007/s000110050743.
26. Leib SL, Clements JM, Lindberg RL, Heimgartner C, Loeffler JM, Pfister LA, Tauber MG, Leppert D. 2001. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124:1734-1742. http://dx.doi.org/10.1093/brain/124.9.1734.
27. Meli DN, Loeffler JM, Baumann P, Neumann U, Buhl T, Leppert D, Leib SL. 2004. In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex. J. Neuroimmunol. 151:6-11. http://dx.doi.org/10.1016/j.jneuroim.2004.01.026.
28. Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac CL, Täuber MG, Neumann U, Leib SL. 2006. Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect. Immun. 74:3890-3896. http://dx.doi.org/10.1128/IAI.01949-05.
29. Whittaker M, Floyd CD, Brown P, Gearing AJ. 1999. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99:2735-2776. http://dx.doi.org/10.1021/cr9804543.
30. Close DR. 2001. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60(Suppl. 3):iii62-iii67. http://dx.doi.org/10.1136/ard.60.90003.iii62.
31. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM. 1998. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum.41:1639-1644.http://dx.doi.org/10.1002/1529-0131(199809)41:9 <1639::AID-ART15>3.0.CO;2-0.
32. Hemmings FJ, Farhan M, Rowland J, Banken L, Jain R. 2001. Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis. Rheumatology (Oxford, England) 40:537-543. http://dx.doi.org/10.1093/rheumatology/40.5.537.
33. Beck G, Bottomley G, Bradshaw D, Brewster M, Broadhurst M, Devos R, Hill C, Johnson W, Kim HJ, Kirtland S, Kneer J, Lad N, Mackenzie R, Martin R, Nixon J, Price G, Rodwell A, Rose F, Tang JP, Walter DS, Wilson K, Worth E. 2002. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase. J. Pharmacol. Exp. Ther. 302:390-396. http://dx.doi.org/10.1124/jpet.302.1.390.
34. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, Johnson WH, Nixon JS, Rose F, Sutton B, Wilson K. 1997. Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br. J. Pharmacol. 121:540-546. http://dx.doi.org/10.1038/sj.bjp.0701150.
35. Hilpert H. 2001. Practical approaches to the matrix metalloproteinase inhibitor Trocade® (Ro 32-3555) and to the TNF-α converting enzyme inhibitor Ro 32-7315. Tetrahedron 57:7675-7683. http://dx.doi.org/10.1016/S0040-4020(01)00720-7.
36. Blaser C, Wittwer M, Grandgirard D, Leib SL. 2011. Adjunctive dexamethasone affects the expression of genes related to inflammation, neu-rogenesis and apoptosis in infant rat pneumococcal meningitis. PLoS One 6:e17840. http://dx.doi.org/10.1371/journal.pone.0017840.
37. Gianinazzi C, Grandgirard D, Imboden H, Egger L, Meli DN, Bifrare DY, Joss PC, Täuber MG, Borner C, Leib SL. 2003. Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis. Acta Neuropathol. 105:499-507. http://dx.doi.org/10.1007/s00401-003-0672-7.
38. Gehre F, Leib SL, Grandgirard D, Kummer J, Buhlmann A, Simon F, Gaumann R, Kharat AS, Tauber MG, Tomasz A. 2008. Essential role of choline for pneumococcal virulence in an experimental model of meningitis. J. Intern. Med. 264:143-154. http://dx.doi.org/10.1111/j.1365-2796.2008.01930.x.
39. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. 2012. Cutoff Finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 7:e51862. http://dx.doi.org/10.1371/journal.pone.0051862.
40. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. 2011. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin. Microbiol. Rev. 24:557-591. http://dx.doi.org/10.1128/CMR.00008-11.
41. Gerber J, Nau R. 2010. Mechanisms of injury in bacterial meningitis. Curr. Opin. Neurol. 23:312-318. http://dx.doi.org/10.1097/WCO.0b013e32833950dd.
42. Leib SL, Kim YS, Chow LL, Sheldon RA, Tauber MG. 1996. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J. Clin. Invest. 98:2632-2639. http://dx.doi.org/10.1172/JCI119084.
43. Mitchell L, Smith SH, Braun JS, Herzog KH, Weber JR, Tuomanen EI. 2004. Dual phases of apoptosis in pneumococcal meningitis. J. Infect. Dis. 190:2039-2046. http://dx.doi.org/10.1086/425520.
44. Grandgirard D, Leib SL. 2010. Meningitis in neonates: bench to bedside. Clin. Perinatol. 37:655-676. http://dx.doi.org/10.1016/j.clp.2010.05.004.
45. Liedtke W, Cannella B, Mazzaccaro RJ, Clements JM, Miller KM, Wucherpfennig KW, Gearing AJ, Raine CS. 1998. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:35-46. http://dx.doi.org/10.1002/ana.410440110.
46. Snoek-van Beurden PA, Von den Hoff JW. 2005. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38:73-83. http://dx.doi.org/10.2144/05381RV01.
47. Mitchell AJ, Yau B, McQuillan JA, Ball HJ, Too LK, Abtin A, Hertzog P, Leib SL, Jones CA, Gerega SK, Weninger W, Hunt NH. 2012. Inflammasome-dependent IFN-gamma drives pathogenesis in Streptococcus pneumoniae meningitis. J. Immunol. 189:4970-4980. http://dx.doi.org/10.4049/jimmunol.1201687.
48. Kornelisse RF, Savelkoul HF, Mulder PH, Suur MH, van der Straaten PJ, van der Heijden AJ, Sukhai RN, Hahlen K, Neijens HJ, de Groot R. 1996. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. J. Infect. Dis. 173: 1498-1502. http://dx.doi.org/10.1093/infdis/173.6.1498.
49. Grandgirard D, Bifrare YD, Pleasure SJ, Kummer J, Leib SL, Tauber MG. 2007. Pneumococcal meningitis induces apoptosis in recently postmitotic immature neurons in the dentate gyrus of neonatal rats. Dev. Neurosci. 29:134-142. http://dx.doi.org/10.1159/000096218.
50. Ramilo O, Mustafa MM, Porter J, Saez-Llorens X, Mertsola J, Olsen KD, Luby JP, Beutler B, McCracken GH, Jr. 1990. Detection of interleukin 1 beta but not tumor necrosis factor-alpha in cerebrospinal fluid of children with aseptic meningitis. Am. J. Dis. Child. 144:349-352.
51. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. 1995. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res. 703:151-155. http://dx.doi.org/10.1016/0006-8993(95)01089-0.
52. Bogdan I, Leib SL, Bergeron M, Chow L, Tauber MG. 1997. Tumor necrosis factor-alpha contributes to apoptosis in hippocampal neurons during experimental group B streptococcal meningitis. J. Infect. Dis. 176: 693-697. http://dx.doi.org/10.1086/514092.
53. Janser P, Neumann U, Miltz W, Feifel R, Buhl T. 2006. A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg. Med. Chem. Lett. 16:2632-2636. http://dx.doi.org/10.1016/j.bmcl.2006.02.042.
54. Kim KS. 2003. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat. Rev. Neurosci. 4:376-385. http://dx.doi.org/10.1038/nrn1103.
55. Gerber J, Bottcher T, Hahn M, Siemer A, Bunkowski S, Nau R. 2004. Increased mortality and spatial memory deficits in TNF-alpha-deficient mice in ceftriaxone-treated experimental pneumococcal meningitis. Neurobiol. Dis. 16:133-138. http://dx.doi.org/10.1016/j.nbd.2004.01.013.
56. Klebanoff SJ. 2005. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77:598-625. http://dx.doi.org/10.1189/jlb.1204697.
57. Lahrtz F, Piali L, Spanaus KS, Seebach J, Fontana A. 1998. Chemokines and chemotaxis of leukocytes in infectious meningitis. J. Neuroimmunol. 85:33-43. http://dx.doi.org/10.1016/S0165-5728(97)00267-1.
58. Hosokawa T, Nakajima H, Doi Y, Sugino M, Kimura F, Hanafusa T, Takahashi T. 2011. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier. J. Neuroimmunol. 236:81-86. http://dx.doi.org/10.1016/j.jneuroim.2011.04.009.